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Navigating the Third Frontier of Antimicrobial 
Therapy to Support Women’s Health 
Emma Wittman, Neela Yar, Bryan Larsen* 





This paper explores one of the underappreciated reasons for lack of efficacy in 
certain cases of antimicrobial therapy, namely the occurrence of a non-genetic 
resistance to antimicrobial drugs due to a metabolic quiescence of microorgan-
isms. This review has centered on those microorganisms of particular im-
portance in obstetrics and gynecology and accordingly has reviewed the nature 
and extent of the persister phenotype in relation to infectious agents affecting 
women’s health. We show how the quiescent persister microbial phenotype 
represents the next significant issue that could compromise successful antibi-
otic therapy. A brief history of antimicrobial therapy is provided as context for 
the problem posed by the persister phenotype. This review has been focused on 
the current literature having relevance for physicians concerned with women’s 
health. The study of this phenotype has led to increasing understanding of the 
molecular mechanisms for this state which also provides ideas for rational de-
velopment of drug candidates to interdict these organisms in human disease 
and explores the possibility of developing specifically targeted molecules to ad-
dress persisters, research on screening botanicals, existing drugs and chemicals 
to discover novel approaches to the clinical consequence of microbial persisters. 
Of interest in this review, is the return to naturally occurring botanical sub-
stances, first to be used as anti-infectives, now being considered as possible 
agents to address persister microorganisms. Overall this paper aims to provide 
information tailored especially to the obstetrics and gynecology specialists. 
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1. Introduction 
Infectious disease is no respecter of gender, despite the fact that there are exam-
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ples of infectious diseases for which attack rates are greater in men than women 
and other examples in which women have the greater burden of disease. But the 
special consideration for women is those conditions specifically related to the 
reproductive apparatus and by extension, the possibility of infectious conditions 
spreading to or otherwise compromising the fetus with consequences greater in 
the fetus than in the mother. 
The topic addressed here relates to both genders but as therapy is considered, 
the special case of obstetrical and gynecologic implications will be highlighted. 
2. Before Germ Theory 
From time out of mind, human history has recognized the concept of contagion, 
and astute observations led to approaches to deal with communicable diseases 
that were based on distance or avoidance. Communicable skin diseases were 
known to the ancients. Leprosy, for example, is believed to have been mentioned 
in Hippocratic writing (460 BC) and may have related to various skin conditions 
including what is known today as leprosy or by eponym as Hansen’s disease. 
Quarantine, distancing or banishment was often involved and related, at least in 
part, to the recognition of communicability. Even though it was not until 1873 
that the etiologic bacterium was discovered, the ancients treated leprosy as an 
infectious disease. 
The mechanism of contagion would have to wait until the middle of the 19th 
century when Louis Pasteur and later Robert Koch were able to convincingly 
identify microorganisms as the pathogenic principal in specific diseases.  
3. The First Frontier: Anti-Infective Substances 
3.1. History 
Logic would dictate that if microorganisms are able to cause human disease, a 
method for defeating disease would lie in defeating microbial pathogens. Qui-
nine, found in cinchona bark, had been used to treat malaria by Andean peoples. 
Cinchona bark began to be imported to Europe in the 17th century, but its use 
actually predated Alphonse Laveran’s recognition in 1880 that a causative para-
site was involved in this disease. Certain poisons such as mercury salts were in-
troduced in 1496 for syphilis, even though Treponema pallidum would not be 
identified until 1905. Five years after the discovery of the spirochete, Hata and 
Ehrlich introduced an arsenical, salvarsan, which was the first effective medica-
tion for syphilis. 
Paul Ehrlich, a Prussian Doctor working in the latter years of the 19th century 
found that chemical dyes, particularly methylene blue, had an affinity for mi-
croorganisms and reasoned that there could be other dyes or chemical com-
pounds that might be discovered or developed with specificity for microorgan-
isms. His recognition that dyes had selectivity for cellular components led him to 
the astute conclusion that unless a compound can bind to the etiologic microbe, 
it cannot exert a damaging effect on it. In particular, he expressed hope that he 
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would discover “therapia sterilans magna” or a general sterilizing agent that may 
come through the development of a compound that specifically attached to 
pathogen cells as methylene blue did in the case of Plasmodium. Not surprising-
ly, the early work on chemotherapeutic agents focused on dye molecules, most 
notably pursued by Bayer in Germany. The concept of Ehrlich became popular-
ized in his term “charmed” or “magic bullet”. Combining his knowledge of 
chemistry and medicine, he was involved in developing the aforementioned 
arsphenamine as an improved treatment for syphilis. Perhaps as important as 
the drug itself was the birth of the concept of chemotherapy for infectious dis-
ease. 
Syphilis, it should be pointed out, has been endemic since about 1500 and has 
been responsible for unaccountable levels of morbidity and mortality over the 
centuries. One particular concern continuing up to the present is congenital 
syphilis, which can result in fetal demise or severely compromised offspring. 
Despite the availability of penicillin as the most effective therapeutic, in 2017 
congenital syphilis reached a 20 year high in the US with more than 900 babies 
infected [1]. This occurs in the face of effective methods for screening, even in a 
high-resource nation. 
Despite the unfortunate fact that syphilis treatment opportunities are some-
times missed, the historical legacy of the Ehrlichian concept of a magic bullet is 
modern day chemotherapeutic and antibiotic compounds. These therapies have 
saved countless lives and have become the mainstay of treatment and for some 
diseases, and prevention. Chemotherapeutics such as sulfonamides became 
available around 1935 and were used for streptococcal infections and in relation 
to women’s health were used to treat “childbed fever” which was predominantly 
the result of Group A streptococcus. Their use was limited by several factors that 
included the bacteriostatic effect, allergies and limitations due to endogenous fo-
lic acid. 
The antibiotic concept was expanded when penicillin was discovered by Al-
exander Fleming in 1928 (though practical use would have to wait until 1942), 
who showed that an inhibitor of Streptococcus was elaborated by another mi-
croorganism—a mold. Accordingly, many more naturally-occurring antimicro-
bials and synthetic and semi-synthetic antibiotic usage ensued. By the middle of 
the twentieth century it seemed infectious disease was destined to be conquered 
if only the right drug compounds might be discovered or invented.  
3.2. Antimicrobials of Mono-Etiologic Infections in Women 
Antibiotics have had an important impact on some of the infectious disease 
threats to women and infants. As noted above, penicillin has remained the 
mainstay of syphilis therapy and is guided by detailed protocols in the CDC lit-
erature which very specifically addresses syphilis in pregnancy and neonates. It 
is striking that penicillin remains the required treatment more than 70 years af-
ter its discovery. 
E. Wittman et al. 
 
 
DOI: 10.4236/ojog.2020.1080096 1014 Open Journal of Obstetrics and Gynecology 
 
Likewise, Group B streptococcal infection of infants with early or late onset 
presentation, with its grave consequences, has been addressed by prophylactic 
use of penicillin or ampicillin. This is employed in conjunction with testing pro-
tocols during pregnancy. The major reason for using vancomycin as an alterna-
tive to penicillin or related compounds is penicillin allergies and not the lack of 
susceptibility of the organism to beta-lactam antibiotics. 
Another Gram-positive pathogen of concern in pregnancy is Listeria 
monocytogenes, which causes a 13-fold greater infection rate among pregnant 
women compared to the general population. Overall cases of infection are still 
low, in the range of 0.27/100,000, according to the CDC. This foodborne illness 
is usually prevented through avoidance of some foods and careful preparation 
and handling of foods. However, when an antibiotic is indicated the drug of 
choice is ampicillin. 
The intrinsic susceptibility of microorganisms to the inhibitory action of an-
timicrobials defines the spectrum of activity for the antibiotic. While the spec-
trum of activity can be relatively stable for some microbe-antibiotic combina-
tions as indicated above, the occurrence of antibiotic resistance represents a 
challenge to therapy as discussed below. 
3.3. Antimicrobial Therapy of Polymicrobial Infections in Women 
Particular to women’s health, are endogenous infections that arise from bacteria 
that are commensal in the lower genital tract. Some of these organisms are 
known to be found as polymicrobial communities involved in pelvic inflamma-
tory disease, tubo-ovarian abscesses, post-hysterectomy surgical infections, 
chorioamnionitis, postpartum endometritis and other related infections. Prior to 
the advent of molecular methods for characterizing the cervical and vaginal 
microbiota, culture-based techniques demonstrated that among healthy women, 
Gram negative facultative organisms as well as Gram negative and positive 
strictly anaerobic bacteria could be present. These organisms could become the 
polymicrobial inoculum in infections arising after procedures or parturition. 
Because cultures of organisms involved in endometritis and post-hysterectomy 
infections resembled the lower genital tract, empirical therapy was based on ob-
taining a spectrum of activity to cover most of the common microbial species. 
Early work done on postoperative and postpartum cultures in women demon-
strated that in addition to bacteria present in the lower genital tract prior to the 
procedure, within a few days from the operative event a proliferation of Gram 
negative facultative and anaerobic organisms was observed. This phenomenon 
informed both concepts of therapy of post-procedure infections, but also sug-
gested how prophylactic antibiotics might be used to interdict this shift in lower 
tract microbiome composition [2] [3]. 
Antibiotic treatment regimens that covered Gram negative and positive as 
well as anaerobic organisms led to empiric use of combinations of antibiotics 
such as clindamycin-gentamicin, or for monotherapy, ampicillin-sulbactam, or 
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cephalosporin such as cefoxitin with spectrum extending to Gram negative an-
aerobic organisms. Thus, the first frontier for therapy involved the discovery or 
development of a large array of antibiotic compounds, an expansion of the un-
derstanding of which organisms are involved in obstetrical and gynecologic in-
fections and the antimicrobial spectrum inherent in the therapeutic drugs. 
4. The Second Frontier: Drug Resistance 
4.1. Resistance—Antibiotic’s Other Property 
Some of the greatest challenges in antimicrobial therapy have come with ac-
quired antibiotic resistance, though resistance mechanisms, particularly to be-
ta-lactam antibiotics, have existed before the discovery of penicillin. A more ex-
pansive discussion of this topic may be found in the excellent review by Bush, 
which summarizes the large diversity of beta-lactamases known currently and 
the parallel development of new drugs [4]. Resistance mechanisms to other clas-
ses of antibiotics likewise have challenged physicians as the number of antibiotic 
resistant strains are continuously emerging. 
Several approaches to antimicrobial resistance have occurred in parallel with 
focus on various topics. While the intent here is not to review each of these, it is 
useful to realize that the epidemiology of drug resistance has documented the 
existence and increases seen in clinical settings. One approach to antibiotic re-
sistance has been the development of semi-synthetic analogs of antibiotics and as 
well as discovery and development of new classes of drugs, perhaps no better il-
lustrated than in the early development of beta-lactamase-resistant penicillins. 
Because antibiotic use and abuse introduces selective pressure for increased 
prevalence of antibiotic resistant strains, the whole topic of antibiotic steward-
ship has developed and ecological considerations, including antibiotic use in ag-
riculture, has played a part in the overall topic of antibiotic resistance. Finally, 
understanding of the chromosomal and non-chromosomal mechanisms of re-
sistance as well as transferring resistance among strains has been vigorously 
pursued by molecular biology approaches. 
Perhaps one of the most volatile areas of drug resistance pertains to Neisseria 
gonorrhoeae. In a historical review, Hook and Kirkaldy note that, “…development 
of resistance to antibiotics widely used for treatment appears to be an inexorable 
process” [5]. Both genders are affected by this sexually transmissible pathogen, 
but certain aspects of morbidity seem to have special relevance to women, in-
cluding the tendency toward asymptomatic occurrence, progression to upper 
tract complications and the possibility of intrapartum infection of vaginally de-
livered infants. A review by Unemo and Schafer invoked the term “super bug 
status” as they presented a timeline of the demise of the clinical usefulness of 
emerging (then declining) therapies including sulfonamides, penicillin, penicil-
lin plus streptomycin, spectinomycin, tetracycline, erythromycin, azithromycin 
and fluoroquinolones [6]. Current CDC guidelines for uncomplicated gonorrhea 
specify dual therapy with ceftriaxone and azithromycin but continued modifica-
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tions in therapy will undoubtedly be required in the future. 
4.2. Resistant Organisms and Women’s Health 
Antimicrobial resistance is also a concern for Candida albicans which is oppor-
tunistic, being at times a lower genital tract commensal as well as under alternate 
circumstances a source of vaginal symptoms. Other less frequently encountered 
Candida species may also have limited susceptibility to antifungal drugs. Multi-
ple mechanisms are in play including efflux pumps, mutations involving cell wall 
biosynthesis, and physical barriers to antifungal drug penetration in the form of 
biofilm. While the classes of antimicrobials available to treat fungal infections 
are limited and amphotericin B, for example, requires cautious use due to tox-
icity, a number of novel approaches to defeating antifungal drug resistance are 
being explored as described in great detail in a recent review [7]. 
Fortunately, Toxoplasmosis is an uncommon threat to pregnancy in the US 
but remains highly prevalent elsewhere in the world and is a known threat for 
congenital infection. According to recent information there are known treat-
ment failures and demonstrated resistance to pyrimethamine and sulfadiazine 
and clinical consequences remain under scrutiny [8]. Another parasite that is a 
threat in pregnancy is Plasmodium, especially in falciparum malaria. Current 
concerns about drug resistance are related to the presence of strains with P. fal-
ciparum chloroquine resistance transporter (PfCRT), which has been reported to 
alter malaria treatment in some geographical areas [9]. 
While the emphasis thus far has been on the refractoriness of individual mi-
crobial species to antibiotic or antifungal drugs, the lower female genital tract is 
known to have a diverse microbiome and dysbiotic conditions are associated 
with symptoms as in the case of bacterial vaginosis. The first descriptions of 
bacterial vaginosis (BV) were accompanied by the discovery of an organism now 
known as Gardnerella vaginalis and there was enthusiasm at that time that this 
organism was the etiologic agent of what was then called “non-specific vagini-
tis”. Over many years and with both debate and fundamental research, it became 
accepted that BV represents a state of microbial diversity with a diminution of 
lactobacilli and an abundance of anaerobic organisms. In the context of this pa-
per, it should be noted that the antibiotic treatment of this condition is oral 
metronidazole or topical clindamycin, but treatment is not directed toward just 
one microbial species. In contrast to more classically understood infections, this 
is a polymicrobial condition and the goal of therapy is not necessarily directed at 
Gardnerella vaginalis alone, but at a microbial community. 
BV is also characterized by the presence of a biofilm which is also polymicrobial 
and the biofilm is considered to be an important part of the condition and likewise 
an important part of maintaining the microbial community. In addition, because 
of the refractoriness of biofilms to antibiotic therapy, the biofilm is considered to 
be a significant element in recrudescent or recurrent BV. BV is common among 
reproductive aged women and is a risk factor for other conditions such as pelvic 
inflammatory disease, preterm birth and postpartum infection and is a continuing 
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concern for the obstetrician-gynecologist. The biofilm that complicates antibi-
otic therapy is part of a larger matter which is considered in the next section. 
5. The Third Frontier: The Persister Phenotype 
Genetics plays a very large role in the overall phenomenon of microbial re-
sistance to therapeutic antibiotics through a broad variety of mechanisms. 
Chromosomal or extrachromosomal mutations affecting the target of an antibi-
otic may be ways of genetically acquiring resistance. The results of these genetic 
changes lead to a strain that propagates its resistance through future rounds of 
replication. Efflux pumps are also involved in some cases of resistance to anti-
microbial drugs and these may have a genetic upregulation of an existing gene. 
But in this section, emphasis is given to a mechanism of refractoriness to anti-
microbial therapy that is epigenetic and related to phenotype rather than geno-
type. 
An excellent working definition of the persister is provided by Barrett and 
co-workers: “A subpopulation of slow-growing or growth-arrested cells that 
have a decreased susceptibility to killing by normally effective cytotoxic agents. 
Persisters survive treatment with drugs because of their altered metabolism dur-
ing a temporary state of quiescence and are genetically identical to other, 
drug-susceptible cells in the population. Persisters may arise stochastically, or in 
responses to environmental cues such as nutrient starvation” [10]. 
5.1. Elaborating the Persister Phenotype 
One of the first general concepts taught in microbiology is the kinetics of micro-
bial (bacterial) growth, which takes the form of the growth curve that consists of 
the familiar lag phase, logarithmic phase, stationary phase, and the death phase. 
The classical growth curve is readily demonstrated in a closed system, such as a 
broth culture containing a finite amount of nutrient and with no means of elim-
inating bacterial end products. Natural environments—including infected living 
hosts—are open systems and would not be expected to have such a precise pop-
ulation dynamic. But the discovery of quorum sensing is somewhat analogous to 
the stationary phase in closed cultures, and its characteristics have shaped the 
understanding of many infectious processes. 
Microbial ecologists have long known that in natural environments, microor-
ganisms undergo attachment to surfaces, growth in situ, quorum sensing and 
formation of biofilm. Biofilms are characterized by physical organization that 
allows them to resist removal through shear forces. The organisms within the 
biofilm matrix also show a high level of refractoriness to antibiotics and disin-
fectants. The differences between planktonic growth and biofilm have genetic 
determinants that guide organisms’ transition to this highly resistant state. The 
three dimensional structure of biofilms and the extracellular matrix that both 
fixes the organism to a substrate and provides a barrier has often been cited as 
the reason why biofilm organisms are refractory to disinfectants and antibiotics. 
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However, the abundance of persisters within the biofilm matrix are also in play. 
The process of biofilm formation has elements related to microbial stress re-
sponses which provide for microbial survival during adverse conditions and, as 
will be noted later, processes in biofilm formation and persister formation have 
overlapping elements.  
Biofilm has profound implications for medicine, first as an organized mass of 
microorganisms that form on abiotic surfaces of medical devices such as cathe-
ters or other implanted materials. The organisms that are part of the biofilm are 
difficult to eradicate, but also provide a potential source of systemic infection 
when viable organisms break away. In addition, biofilm can form on biotic 
structures. The heart valve vegetation long known to be associated with alpha 
hemolytic streptococci represents the first recognized medical problem associ-
ated with biofilm. Other normally colonized sites such as alimentary tract and 
genital tract can host biofilms as well, and these have been associated with diffi-
culty in providing therapy to the patients colonized in this manner. In contrast, 
biofilms may be a mechanism through which beneficial indigenous organisms 
can stably associate with a host, which indicates that biofilms are not always 
threats to health. 
Related to the altered state of microorganisms in biofilm is a concept that had 
its roots in the earliest history of antibiotic use. Early observations with penicil-
lin showed that cultures exposed to this bactericidal treatment were accompa-
nied by killing of microorganisms, but the process was not complete. This same 
phenomenon was observed with other physical and chemical sterilization meth-
ods. As currently understood, microorganisms possess a pathway that leads to 
some members of a microbial community to enter a state of dormancy and in-
stead of multiplying as rapidly as the environment will support, some stochasti-
cally-determined percentage of planktonic cells exist in this indolent state, which 
renders them insusceptible or tolerant to antibiotics and other antimicrobial 
agents. 
5.2. Semantic Cautions 
As mentioned above, survivor populations in antibiotic-treated Streptococcus 
cultures were recognized decades ago. Describing these cells as persisters rather 
than survivors has become a more recent nomenclature. Beyond the strictly ac-
ademic interest in persistership, there is obviously a clinical consideration as 
well. The clinical implication of this particular microbial phenotype is the possi-
bility that recurrent or recrudescent symptomatic disease may arise from the 
presence of persisters re-growing after apparently effective therapy. 
In a semantically pure sense, persistent disease is to be distinguished from the 
term persister referring to the microbial phenotype, despite the fact that persis-
tent disease may be the result of persister microorganisms. However, it is also 
possible that persistent or recurrent disease may arise from pharmacologic con-
siderations such as early termination of a bacteriostatic drug or from genetically 
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resistant organisms representing that second frontier of treatment. The latter 
situation could be confirmed by re-isolation of the causative microorganism 
coupled with evidence that the organism is stably-resistant to the therapeutic 
drug. 
Perhaps no better source for clarity surrounding the distinction between 
persister organisms and persistent infection and the relevance and relationship 
between them will be found in the treatment of the topic by Zhang [11]. Here is 
also described two types of persisters, non-growing and slow growing and the 
relationship to other phenomena such as bacterial L-forms and biofilm bacteria. 
The purpose of this paper will be best served by considering the persister phe-
notype generally and unless otherwise noted, will not focus on different persister 
types. In addition, it should be noted that additional terms (in addition to survi-
vor) have been applied to persisters, including dormant cells, quiescent cells or 
inert cells.  
5.3. Breadth of the Persister Phenomenon 
Research on persisters shows that these organisms are associated with a vast ar-
ray of bacterial species and also extend to fungal pathogens as well. Zhang de-
scribes it as a phenomenon common to all bacteria. It would follow that even 
though the persister phenotype has not been demonstrated in a particular mi-
crobial species, it may nevertheless occur and could link to prolongation of clin-
ical diseases [11]. Demonstration of the persister phenotype among bacteria re-
quires experiments conducted on organisms that are capable of laboratory culti-
vation, and some of the organisms of interest relative to women’s health may be 
difficult or impossible to cultivate. As with organisms only identified through 
molecular taxonomy, it may be possible to predict the ability of organisms to 
elaborate persisters through pathways identified by gene sequencing, even 
among organisms that cannot be cultivated. 
Because persister organisms have a relationship to persistent disease, it be-
comes a collateral interest to know why some diseases do not seem to be persis-
tent (for example streptococcal pneumonia) versus others that are persistent 
(like tuberculosis). This worthy topic will not be explored in this paper, but 
probably at a minimum, involves differences in the manner in which the innate 
and adaptive immune systems handle different microbial species in vivo.  
In addition to the assertion that persister generation applies to all bacteria, it 
also applies to eukaryotic organisms as well. Among the organisms with rele-
vance to women’s health, Candida albicans and other Candida species are of sig-
nificant importance and have been extensively studied for their pathways to 
persister generation [12]. As noted in the next section, eukaryotic and prokary-
otic mechanisms of persister generation differ, but may have similar implica-
tions for chronicity of infectious disease. Protozoan persisters have been de-
scribed and even in the case of cancer cells refractory to chemotherapy, persister 
cancer stem cells may play a role in prolongation of disease [13] [14]. 
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Some viral diseases such as those caused by the Human Herpes Virus, have 
mechanisms for prolonging the life of their host cells [15]. Cytomegalovirus, a 
concern for pregnant women who may transmit the virus to their offspring 
transplacentally, is able to induce a specific phenotype of macrophage that is 
long-lived and resists apoptosis [16]. Other examples that have unique molecular 
mechanisms exist, but will not be elaborated here. To focus more directly on 
pathogenic microorganisms that have a specific persister phenotype it will be 
useful to consider the epigenetic and metabolic properties of bacterial and fungal 
persister cells. 
5.4. Metabolic Mechanisms of Persistence 
Bacterial persister phenotypes have a “high tolerance” to antibiotics and are able 
to survive various doses of bactericidal or bacteriostatic treatments. Once the an-
tibiotics are removed from the environment, the bacteria will begin dividing 
again and resume the metabolic processes of normally functioning cells. These 
persisters can also survive other environmental stressors, including nutrient de-
pletion. The persister phenotype is a dormant state that enables the bacteria to 
survive the environmental stress and antibiotics without reliance on any antibi-
otic-resistance genes. The general consensus developing around the persister 
phenotype in bacteria relates to a model known as the Toxin-Antitoxin (T-AT) 
model. In this system, the Toxin downregulates cellular activities such as replica-
tion, biosynthesis and growth. The toxin suppressed by the antitoxin under de-
sirable conditions such as logarithmic growth, in the presence of nutrient reple-
tion. However, under stringent conditions, the Antitoxin is degraded. This al-
lows the Toxin to apply brakes to the cellular systems and prompt the cell into 
dormancy [17]. Klimina et al. found that numerous strains of Lactobacillus 
rhamnosus had T-AT systems, therefore driving these strains to express persister 
phenotypes to evade and survive environmental stressors [18]. From the stand-
point of gynecology, probiotic lactobacillus may be spared under conditions of 
environmental stress. Conversely, the T-AT system may promote the survival of 
pathogenic organisms under the stress of therapeutic drugs. 
Yeast species have also been found to contain persister phenotypes, but fungal 
persistership is mechanistically different from that of bacteria. Yeast persisters 
can survive antimicrobial agents too, and resume their normal cellular activities 
and growth once the agents are removed. Eukaryotic persisters, like prokaryotic 
persister phenotype, are not genetically transmitted. The metabolic machinery 
that allows for persistence is genetically programmed, but the persister state it-
self is not inherited. It should be mentioned that some mutations have been 
found in yeast to promote a propensity to produce persisters (high persister 
strains) and the propensity is heritable [19] [20]. 
In yeast species, the target of rapamycin complex 1 (TORC1) pathway alters 
cell growth by various mechanisms: cell cycle initiation and translation of ribo-
somal proteins. TORC1 itself is in turn regulated by rapamycin and cell nutri-
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ents. Rapamycin treatment induces a stressful environment for the yeast and in-
creases expression of the persister phenotype. Bojsen et al. did a study with Sac-
charomyces cerevisiae mutants, which had inhibited TORC pathways and found 
that they had an increased persistence after amphotericin B treatment. This re-
sult made it appear that amphotericin B induces persister phenotypes itself by 
applying environmental stress. Candida albicans and Candida glabrata have 
been found to have a higher persister phenotype when exposed to rapamycin. 
When yeast cells are subjected to a stressor, the TORC1 pathway is inhibited or 
downregulated, allowing the cell to enter a dormant phase and take on a 
persister phenotype [21]. 
5.5. Identification of Persister Organisms  
The percentage of a population growing in culture which are persister cells 
seems to be smallest in logarithmic planktonic growth. As a culture reaches its 
stationary phase, when replication and death rates equalize, more persisters are 
to be found. Finally, when microorganisms form biofilm, the biofilm is likely to 
harbor the highest percentage of persisters. 
As with studies of the bacterial growth curve, persistership may best be 
demonstrated in vitro and perhaps cannot truly and irrefutably be demonstrated 
in vivo. Demonstrating persisters is closely related to the definition of persister, 
which is a cell that remains viable under conditions that ordinarily render cells 
in the same culture non-viable. In other words, if an antibiotic is added to a 
growing culture of bacteria and the culture is allowed to incubate until killing 
should be complete, subculture shows that a number of cells will be able to re-
cover in fresh media, though their recovery will be characterized by a very slow 
growth rate. This release from the persister state also seems to vary within the 
same culture, with some individual cells rebounding faster than others. Persister 
resuscitation results in small colonies described as “deep persisters” and larger 
colonies described as “shallow persisters” while viable non-persisters produce 
the largest colonies. 
This phenomenon can be demonstrated on agar plates on which a presumably 
sterilized culture is plated. Over a period of time small colonies will begin to 
form, much slower than normal colonies would. These colonies, though small, 
will be of varying sizes which implies that persisters recovering from their 
persister state have differing levels of indolence, even in a pure culture of the 
same species. This variation among persisters has led to the concept of deep and 
shallow persisters, somewhat analogous to deep or shallow sleep.  
5.6. Persisters in Obstetric and Gynecologic Infections 
5.6.1. Bacteria 
Many bacterial species are involved in infections or related conditions that im-
pinge on the wellbeing of female patients. In the paragraphs that follow, we 
briefly catalog significant species that have been documented to produce 
persisters. If persisters have not been identified, we will discuss the evidence that 
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persisters are likely because the persister phenotype is considered a common 
feature of bacteria and the absence of persisters would generally be considered 
anomalous. This discussion has been organized generally in the order of preva-
lence of these organisms. 
Bacterial vaginosis (BV) is one of the most commonly encountered conditions 
in women. While it is considered to be a dysbiotic condition of the vaginal 
microbiome, virtually all cases have an abundance of Gardnerella vaginalis in con-
cert with a diversity of Gram negative bacteria and reduced abundance of Lactoba-
cillus species. Although we have not identified specific reports of persisters among 
Gardnerella, several clinical features are consistent with a role for persisters. De-
spite its frequency, recurrent episodes are common, even after treatment with 
metronidazole or clindamycin. One reason for recurrent BV may be polymicrobial 
biofilm that includes Gardnerella vaginalis. Biofilms in general are considered to 
have a significant level of persisters as will be subsequently addressed further. 
This polymicrobial biofilm is characteristic of BV. Such a biofilm promotes re-
current infection in over 50% of patients within 6 - 12 months after initial treat-
ment [22]. A 2010 experiment testing the response of the polymicrobial biofilm 
to the antibiotic moxifloxacin found that within 5 days post-treatment, a surge 
in Gardnerella vaginalis cell numbers due to persisting biofilm was identified 
[23]. Subsequent studies suggested inhibition of biofilm production using 
quorum-inhibiting agents or disruption of existing biofilm using boric acid 
could, in combination with bacteriostatic or bactericidal medications, provide 
improved efficacy in preventing recurrence [24] [25]. 
Urinary tract infection, frequently due to Gram negative enteric bacteria, may 
also be a recurrent clinical problem and persister organisms with mucosal bio-
films are implicated. UTIs commonly occur during pregnancy with further 
complications such as pyelonephritis and increased risk of maternal sepsis, pre-
term labor, and premature delivery in pregnant women [26]. Escherichia coli is 
the most common bacterial pathogen of UTI in women and persister popula-
tions have been identified in a number of studies [27] [28]. Literature suggests 
that overexpression of chromosomal Type II TA toxin molecules may be related 
to development of persistership by inhibiting cell growth after exposure to envi-
ronmental stressors [27] [29]. Although this is a well-studied phenomenon, it is 
unclear as to whether the TA system is the main mechanism by which 
persistership arises and the exact role of (p)ppGpp signaling (see later discus-
sion) drives the persister generation [27] [30]. This persister-development model 
has been applied to different types of bacteria to explain how persisters arise and 
is currently being further studied.  
Historically some of the earliest evidence that antibiotic survival was due to 
the persisters in a population was discovered among Streptococci. Group A 
Streptococcus (GAS) was scourge in obstetrics in the mid 1800s as “childbed fe-
ver”, stemming from GAS infection, contributed to significant maternal mortal-
ity. Today GAS infections in developed countries are infrequent, but still cause 
about 40% of septic deaths among patients with postpartum endometritis, ne-
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crotizing fasciitis, and along with Staphylococcus aureus, toxic shock syndrome 
[31]. Biofilm formation in GAS has been documented and hypothesized to be 
part of the cause for failed antibiotic treatment of GAS infections. The antimi-
crobial resistance of GAS biofilms can be partly attributed to the fact that cells 
within the biofilm have reduced metabolic activity, which typifies the persister 
phenotype [32]. Streptococcus mutans and Streptococcus suis persister pheno-
types have been identified which furthers the notion that GAS organisms likely 
have persister phenotypes as well [33] [34]. 
Group B Streptococcus (GBS) is found within the gastrointestinal tract and 
genitourinary tract as a commensal organism in as frequently as 30% of women. 
GBS has declined as a cause of perinatal and neonatal disease due to aggressive 
screening and prophylaxis programs, but presence and continued colonization 
of women remains a cause for vigilance. Korir et al. state GBS is the leading 
cause of neonatal sepsis and meningitis, adding to the importance of treating 
and eradicating these infections in pregnant patients, which unfortunately may 
recolonize the vaginal flora even after antibiotic treatment. Different GBS strains 
can survive inside macrophages, evade the host defense and lead to disseminated 
infection. GBS surviving antibiotic treatment can also be partly attributed to its 
ability to form biofilms, which as previously mentioned hints at the fact that 
GBS can undertake persister phenotypes [35]. The variety of streptococcal spe-
cies found to have persister phenotypes suggests a commonality that should en-
compass GBS. 
Chlamydia trachomatis is another high-prevalence infection with significant 
consequences for the female patient. In addition to its prevalence as primary 
sexually transmitted infection, it is associated with the subsequent complications 
of salpingitis, tubal scarring, ectopic pregnancy, tubo-ovarian abscess and peri-
tonitis. This Gram negative obligate intracellular bacterium has been shown to 
have an interesting persister form. Chlamydia is generally characterized as hav-
ing two different forms, an infectious elementary body (EB) that is extracellular, 
and a replicative reticulate body (RB) that is intracellular. When exposed to 
stressors like iron deprivation, Beta-lactam antibiotics or Fosmidomycin, a third 
form for the bacteria, the aberrant body (AB), arises. When the stress is re-
moved, the AB then converts back to its normal cell type and resumes cell 
growth and division. The AB is then considered to be a persister phenotype of 
Chlamydia trachomatis [36]. The persister phenotype allows C. trachomatis to 
evade antibiotic treatment and reestablish an infection once the drug treatment 
is finished. This knowledge of Chlamydia persistership needs to be utilized to 
create antibiotics that will directly target the persister cells and prevent recurrent 
infections [37]. 
Neisseria gonorrhoeae is less prevalent than Chlamydia trachomatis, but can 
also engender complications of pelvic inflammatory disease, tubal infertility, ec-
topic pregnancy and perinatal infections [38] [39]. A literature search did not 
show any studies directly identifying persisters, but because the history of anti-
biotic therapy for Neisseria gonorrhoeae focused mainly on genetic resistance, a 
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search for persister phenotypes deserves further exploration [38].  
Described in the early 1970’s, Lyme disease caused by the Spirochete of the 
genus Borrelia, is characterized by a chronic and recurrent set of symptoms and 
can be extremely challenging to treat even with appropriate antibiotic regimens. 
In a recent review, a detailed discussion of the persister state of Borrelia 
burgdorferi described morphologic and metabolic aspects of this organism as a 
response to antibiotic exposure suggesting that dealing with the persister state in 
these organisms may be exceedingly important in overcoming the chronicity of 
infection [40]. The authors also drew parallels to other chronic infections in-
cluding leprosy, syphilis and tuberculosis. 
With regard to women’s health, Lyme disease is of concern, but certainly less 
studied than Syphilis, another spirochetal disease. A systematic review by 
Waddell et al. found 45 relevant reports in the world literature and while the 
numbers of cases were small, some adverse pregnancy outcomes related to Lyme 
disease were noted and some indication of transplacental infection was reported 
[41]. Syphilis, on the other hand, has a larger literature describing both maternal 
and fetal consequences. Because it cannot be cultivated, there is no demonstra-
tion of the persister phenotype in the literature, although there are references to 
bacterial persistence that seem to relate to persistent infection as opposed to the 
specific phenotype. 
5.6.2. Fungi 
Candida albicans is typically found in the vaginal canal as a commensal organism. 
However, overgrowth and the establishment of biofilm increases the risk of persis-
tent infection [42]. The development of persister cells in infectious Candida 
albicans is well documented and is believed to make up 0.1% - 2% of the total 
number of cells in a biotic biofilm at any one time [43]. Recurrent vulvovaginal 
candidiasis (RVVC) refers to 3 - 4 consecutive Candida infections within a 
12-month period and remains a clinically challenging entity. A 2019 study identi-
fied RAFT-derived polymethacrylates as a more effective treatment for RVVC 
than popular antifungals like clotrimazole and nystatin. Polymethacrylates have 
been found to successfully disrupt biotic biofilm formation on vaginal epithelium 
and therefore inhibit persistership [44]. This has significant implications for 
women who may suffer from undiagnosed or diagnosed HIV/AIDS, which in-
creases the probability of contracting RVVC and recurrent oral thrush. Because of 
its generally significant role among immunocompromised hosts, the literature on 
this organism is voluminous and research efforts to study the persister phe-
nomenon have fostered research but as yet no specific therapy for quiescent 
forms of the organism. 
5.6.3. Protozoa 
Earlier in this paper parasitic infections that are of concern in pregnancy were 
noted and specific parasites of interest were Toxoplasma gondii and the agents 
of malaria, especially P. falciparum. The existence of persisters and their refrac-
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toriness to therapeutic drugs is considered consequential for these organisms 
and in a comprehensive treatment of the topic, a side-by-side comparison with 
characteristics of bacterial persisters is presented [10]. Bacterial persisters are 
genetically identical to non-persisters and for the majority of parasites reviewed, 
the dormant forms are genetically identical to the replicating form. 
Hypnozoites are well-known stages that occur in P. vivax and apparently in 
the liver some stochastically generated forms have long periods of dormancy 
while others revert to schizogony readily. For P. falciparum, the ring form of the 
parasite is refractory to dihydroartemisinin. For Toxoplasma gondii, it is the 
bradyzoite that is the cognate of bacterial persisters. 
5.6.4. Virus  
Although viruses are unable to become “persisters” on the basis of metabolism 
in the same sense that bacteria and fungi can, viruses such as Herpes Simplex 
Virus-1 & -2 and Human Papilloma Virus (HPV) can persist in human hosts. 
One study states that approximately 90% of HPV-infected women will become 
HPV-negative after 2 years, although certain strains of HPV (such as HPV-16 & 
-18) are more likely to lead to persistent latent infection. This persistent infec-
tion can increase risk of cervical and anogenital cancers 20 years down the line 
[45] [46]. In order to maintain persistent infection in host’s daughter cells, HPV 
E2 proteins tether extrachromosomal viral episomes to the host cell’s mitotic 
chromosomes. This results in maintenance replication of viral genomes, which 
ensures that the virus remains in the host’s nucleus without immune system de-
tection and clearance [46]. Prophylactic vaccination with Gaurdasil has proven 
to be an effective measure in preventing infection by HPV-6, 11, 16, and 18.  
Herpes Genitalis is caused by Herpes Simplex Virus (HSV)-1 and -2 and is 
transmitted through direct contact with infected people who have clinically 
manifested herpes genitalis or asymptomatic viral shedding. Primary infection of 
HSV is often asymptomatic and is followed by life-long persistent latent infec-
tion in the local sensory neural ganglions of the region infected. Latent HSV in-
fection can be reactivated by psychological and environmental factors and often 
manifests as skin lesions at mucocutaneous sites. In the case of obstetric patients, 
both primary and recurrent HSV infection of pregnant women can lead to in-
trauterine viral transmission. This can lead to congenital HSV infection, abor-
tion of pregnancy, or stillbirth [47]. 
5.7. The Broader Picture: Stress, Quorum Sensing, Biofilm,  
Persistership 
5.7.1. Growth and Quorum Sensing 
All of the life processes of living organisms are highly integrated and as noted 
previously, the persister phenotype is connected to metabolic activities that are 
highly regulated and metabolic processes connected to persisters, deserve men-
tion as part of the overall place of persisters in the life and death of microorgan-
isms. It is theorized that there are two general ways in which persisters arise, 
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stochastically within an active culture or those that are induced through envi-
ronmental stressors. The spontaneous persisters are enigmatic, as they are chal-
lenging to research and characterize [48]. On the other hand, stress-induced 
persisters are receiving research attention because of the connection to therapy 
of human infections and refractoriness to antibiotics [48]. There are a multitude 
of stressors that promote persister generation including nutritional stress, oxida-
tive stress, antibiotic treatment, heat shock and DNA damage, all resulting in 
organisms that survive adverse environments through quiescence [48] [49]. 
Stress, in turn, is connected to other processes including natural progression of 
organisms from exponential growth to the well-known stationary phase of the 
growth curve. 
5.7.2. Biofilm 
The stationary phase of the growth curve occurring in a closed environment is 
characterized by a depletion of nutrients, accumulation of end products of me-
tabolism and the presence of large numbers of organisms. Quorum sensing is a 
mechanism used by organisms to determine the cell density of their population 
via autoinducers [50]. The autoinducers are “small diffusible signal molecules’’ 
that mediate cell-cell communication [51]. When the concentration of the 
autoinducers reaches and then surpasses a certain threshold, specific gene ex-
pression stimulates quorum-sensing-regulated processes. This means that once 
the population is large enough, biofilm formation and virulence processes are 
regulated via quorum sensing [50]. Bacteria present in biofilms are different 
from free-living bacteria in the sense that they have more tolerance to antibiotics 
and host immune response. It appears that these altered characteristics are be-
cause of the cells’ coordinated efforts and activities that are controlled by quor-
um sensing [51]. The quorum of microorganisms can also sense the presence of 
a surface to allow the generation of biofilm. 
As mentioned before, the T-AT system is involved in the bacterial stress re-
sponse and can alter bacterial metabolism. It has been found that both biofilm 
and quorum sensing can also be influenced by various T-AT systems to help 
promote their communication and formation when the host is exposed to stress 
[52]. Persisters develop from planktonic bacteria collectively forming bacterial 
colonies within three-dimensional biofilms. Because persisters are found inside 
the biofilm’s bacterial community, the host immune response to eliminate 
persister organisms initially rests on its ability to degrade biofilm itself. The 
composition of biofilm is that of a thick, aqueous mass of polysaccharides, ex-
tracellular DNA, proteins and lipids. Biofilm serves as a physical barrier that 
prevents host immune cells from penetrating and phagocytosing biofilm bacte-
ria, thereby leaving non-persister and persister bacteria protected. Thus, dealing 
with biofilm in a clinical setting is a major challenge for the future [53] [54]. 
As a matter of clinical concern, the presence of antibiotics represents a stress-
or that may promote some viable organisms to enter the persister state. Investi-
gators have conducted numerous detailed examinations of the mediators, path-
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ways and results of generalized stress and these findings are informative in the 
context of antimicrobial therapy. 
5.7.3. Generalized Stress 
In the case of stress-induced persisters, the rise of antibiotic persistence is be-
lieved to be mainly due to nutritional or oxidative stress. In the case of nutri-
tional stress, there is evidence that the deprivation of metabolic substrates causes 
an inhibition of normal metabolic processes and therefore suspends growth. 
Conversely, there is also maintenance of high-enough levels of ATP to sustain 
non-growth-related cellular processes in persister cells. This response to nutri-
tional stress is referred to as the “Stringent Response” in the literature. In rela-
tion to oxidative stress, damage to bacterial DNA can elicit the “SOS Response”, 
which can also promote persistership [48]. 
In bacteria the stringent response is connected to (p)ppGpp that serves as an 
alarmone in what is believed to be a second messenger response system activated 
by nutrient depletion. As observed in E. coli, the starvation-induced stringent 
response involves release of (p)ppGpp, which inhibits translation and replication 
while promoting DNA repair [50]. Studies have shown that across multiple or-
ganisms, mutants with an inability to produce (p)ppGpp also have reduced abil-
ity to form persisters. Release of (p)ppGpp has been observed to be stimulated 
by the formation of biofilm itself and is generally accepted to be involved with 
persistership development in general [55]. 
5.7.4. Mediators T-AT 
As previously discussed, bacterial T-AT has been shown to be related to 
persistership in stressful environments and is regulated by the stringent and SOS 
responses [56]. Increased levels of (p)ppGpp activate Type II antitoxin degrada-
tion and therefore increases unregulated “self-intoxication” by toxin [55]. High 
levels of toxin ultimately inhibit bacterial growth and promote cellular dorman-
cy under the right conditions, such as nutrient and oxidative stress. However, 
studies have shown that certain environmental stresses such as phosphate star-
vation, acid stress, and osmotic stress result in upregulation of Type II TA with 
no increase in persister cells [56]. 
5.7.5. The SOS Response 
The SOS response to DNA damage caused by oxidative stress or antibiotic 
treatment serves as a complementary pathway for stress signaling, and triggers 
Type I and II Toxin [56]. The SOS response also promotes DNA repair, which is 
important for persister resuscitation once the stressor is removed. In (p)ppGpp- 
deficient mutants, studies have shown that SOS-deficient mutant cells show a 
decreased number of persisters, particularly when treated with DNA-damaging 
agents [55]. This is related to studies that have observed that the introduction of 
antibiotics as treatment may also be implicated in the development of 
persistership and supports the idea that generalized bacterial stress responses are 
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related to increased persistership [48]. 
6. Looking Ahead 
It may be concluded from the foregoing discussion that microbial quiescence or 
persister phenotype is broadly encountered among microorganisms of concern 
to women’s health. But the follow up question centers on defeating the organ-
isms that persist after other therapeutic measures have been used. Several poten-
tial approaches might address this issue, but few proven methods have entered 
clinical practice. Intact host defenses may be considered as a potential mecha-
nism for managing persisters, but as indicated in an earlier treatment of the top-
ic, knowledge of the host-microbe interaction with persister organisms has not 
been studied extensively. It would be important to investigate whether microbial 
virulence is diminished in quiescent organisms, leading to down-regulated im-
munity or if the quiescent organisms are refractory to host defense mechanisms 
as they are to antibiotics. 
Based on past successes, it may be hoped that chemical antimicrobial and dis-
infecting molecules might emerge that can disable persister cells and inactivate 
them before the re-emerge from the dormant state. At present, the best example 
of a drug that targets persisters is pyrazinamide which interdicts persister sur-
vival through multiple mechanisms including reduction of CoA needed for sur-
vival and disruption of membrane energetics [57].  
As previously mentioned, another intracellular pathogen of interest and con-
cern is Chlamydia trachomatis (as well as other chlamydial species) and in an 
excellent review by Schoborg the factors which promote the persister state which 
consists of AB, distinct from the well-known EB and RB are driven by stressors 
that include beta-lactam drugs and interferon gamma [58]. Interferon gamma 
serves to down-regulate indolamine 2 - 3 dioxygenase to create a dearth of tyro-
sine. In a recent study, the tryptophan operon of chlamydial isolates from a pa-
tient with recurrent disease showed a consistent mutation in the tryptophan bi-
osynthesis pathway that resulted in development of AB’s making a connection 
between persister phenotype and persistent infection [36]. Detailed dissection of 
the pathways involved in generation of persisters will suggest new targets for 
persisters in the future. Other stressors may be involved in AB development in-
cluding iron starvation or other nutrient deprivation which seems to be a com-
mon theme for many types of persister organisms [59]. 
Targeting pathways may depend in part on detailed identification of common 
and unique elements in various microbial strains. Drug design may be based on 
such detailed information, but other approaches are possible. The work of Feng 
et al. [60] explored the stationary phase of Borrelia butdorferi, which is enriched 
with persister organisms. They found dapsone or daptomycin could be em-
ployed in combination with other drugs to reduce persisters. If reliable methods 
can be developed for isolating persisters, chemical, drug or biological reagents 
could be screened for the ability to inactivate persisters while in their quiescent 
E. Wittman et al. 
 
 
DOI: 10.4236/ojog.2020.1080096 1029 Open Journal of Obstetrics and Gynecology 
 
states. With an appropriate screening method, large chemical or drug libraries 
may be screened for new therapeutic candidates. 
The addition of a drug or compound that has the ability to damage the mi-
croorganism even while it is quiescent presents an attractive concept for defeat-
ing persister organisms. With respect to Candida persisters, de Oliveria Santos 
and co-workers have presented an extensive exploration of novel compounds to 
approach drug resistant strains, although their primary concern did not focus on 
the persister phenotype [61]. Their paper describes several substances that are 
associated with human host defense which have promise in this context. These 
include lysozyme, lactoferrin, and small peptides such as beta defensins. 
Defensin peptides (or other synthetic peptides) could alter membrane integrity 
even while the organism is in the quiescent state, and enzymes or other sub-
stances could damage structures such as bacterial cell wall, which may limit the 
ability of organisms to exit the persister state when conditions become condu-
cive to growth. The ability of compounds of plant origin to inhibit drug resistant 
organisms was also raised in the de Oliveria Santos paper. 
Persisters may be indirectly targeted as the persister phenotype is intricately 
involved with microbial stress responses that push populations toward persister 
generation and biofilm formation. As a result of these relationships, the search 
for clinical interventions to prevent biofilm may also prevent the accumulation 
of persisters associated with the biofilm. In their extensive presentation on bio-
films of several Candida species, Cavalheiro and Teixeira discussed many of the 
current efforts directed at preventing biofilm formation [62]. They describe 
many of the treatments that address biofilms on abiotic surfaces, but also men-
tion some of the compounds with potential effect against biofilms forming on 
mucosa. Notably, such plant compounds as phenylpropanoids and terpenoids, 
synthetic peptides and repurposed drugs discovered through screening com-
pound libraries are possible candidates for biofilm interdiction. The parallels 
with compounds mentioned in the previous paragraph are interesting. The role 
of transition to hyphal growth is also significant in biofilm formation and com-
pounds that alter this process, such as aspirin, have intriguing implications [63]. 
A recent study has also indicated lysozyme may be useful in preventing 
Gardnerella biofilms and can accordingly serve as an adjunct to antibiotics [64]. 
Several other natural and synthetic compounds have been directed against 
Gardnerella biofilm including retrocyclin, DNase, chitosan, subtilosin, poly-L-lysine 
and lauramide ethyl ester [65] [66] [67]. Whether these compounds affect 
persisters directly, indirectly, or not at all remains to be established. 
As previously discussed, quorum sensing is also an element in biofilm and 
persister generation and as a consequence, modulation of quorum sensing may 
be another mechanism to indirectly limit persistership. The discovery of multi-
ple quorum sensing and quorum inhibiting mediators in Candida albicans sug-
gests the possibility of rational approaches to recurrent and recrudescent vagini-
tis due to this organism. The breadth of these autocrine mediators is more fully 
described elsewhere but suggests the possibility of several potential targets to ex-
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plore in future work [68].  
There are three main quorum sensing mediators in bacteria specific for Gram 
negative bacteria (acyl homoserine lactone), Gram positive bacteria (autoinducer 
peptide), or for both Gram negative and Gram positives (autoinducer-2) [69]. 
Targeting these is predicted to have beneficial effects on microbial virulence and 
biofilm production. Interestingly, some of the relevant discoveries in this area 
include phytochemicals with activity against Gardnerella vaginalis biofilm and 
the previously mentioned subtilosin which inhibits autoinducer-2 in Gardnerella 
vaginalis [70] [71]. Additional botanicals in the form of essential oil have also 
been studied as inhibitors of biofilm using various bacterial species as test or-
ganisms and activity against Candida biofilms and hyphae development was re-
ported for plant essential oils as well [72] [73]. 
The future for discovering direct and indirect means for addressing the prob-
lem of persisters and in turn, the problem of stubborn and recurrent infections 
seems bright. Some answers will come from better understanding of the molec-
ular processes of persister generation and targeting specific pathways, while oth-
er progress may be made through high throughput screening of drug and chem-
ical libraries. Interest has also turned to natural products from plants and marine 
organisms.  
While in this paper we have presented the matter of microbial persisters as the 
third frontier of therapeutic challenge, we will not identify it as the last. As with 
therapeutics before, resistance is certain to develop and has precedence even as 
PZA is being used against Mycobacterial persisters, evidence for occasional re-
fractoriness to that drug is being reported [57]. 
7. Summary  
In this paper we have contextualized the history of antimicrobial therapy in the 
form of three frontiers, the discovery and development of antibiotics, the threat 
to antibiotics posed by drug resistance and its genetic spread, and the problem 
posed by the persister phenotype which is related to an altered metabolic state of 
quiescence. This phenomenon is widely distributed through the diversity of mi-
croorganisms that affect women’s health. The study of this phenotype has led to 
increasing understanding of the molecular mechanisms for this state which also 
provides ideas for rational development of drug candidates to interdict these or-
ganisms in human disease. Despite the possibility of developing specifically tar-
geted molecules to address persisters, work continues on screening botanicals, 
existing drugs and chemicals to discover novel approaches to the clinical conse-
quence of microbial persisters. The origin of antimicrobials includes naturally 
occurring botanical substances, like cinchona bark. This may seem unsophisti-
cated by current standards, but we are currently turning again to botanicals and 
other natural products for potential answers to the persister problem. 
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